Allogene Therapeutics amendment to a Schedule 13G/A reports beneficial ownership by Arie Belldegrun and affiliated entities of 13,466,383 shares of Common Stock, representing 5.4% of the class. The filing states 243,777,920 shares outstanding as of March 10, 2026. The cover page shows 3,866,329 shares issuable upon exercise of options within 60 days of March 31, 2026.
Positive
None.
Negative
None.
Insights
Belldegrun and affiliated vehicles report a 5.4% stake in Allogene.
The filing attributes 13,466,383 shares to Arie Belldegrun and related entities, with voting and dispositive powers split between sole and shared control as listed. The percentage is calculated on 243,777,920 shares outstanding.
Ownership is concentrated through multiple entities; subsequent disclosures or amendments could clarify voting arrangements or any changes to the exercisable options shown for March 31, 2026.
Schedule 13G/A shows aggregated beneficial ownership and disclaims certain beneficial ownership interests.
The filing expressly states Dr. Belldegrun "disclaims beneficial ownership" of shares held by Vida entities except for pecuniary interests and cites Section 13(d) in limited context. The cover-page rows set out sole/shared voting and dispositive powers used for reporting.
Filing mechanics and aggregated counts are consistent with passive/Section 13 reporting practice; any material change in intent or control would require an updated filing.
Key Figures
Beneficially owned shares:13,466,383 sharesPercent of class:5.4%Shares outstanding:243,777,920 shares+3 more
6 metrics
Beneficially owned shares13,466,383 sharesAggregate reported for Arie Belldegrun and affiliates
Percent of class5.4%Calculated on outstanding shares as of March 10, 2026
Shares outstanding243,777,920 sharesOutstanding common stock as of <date>March 10, 2026</date>
Options exercisable within 60 days3,866,329 sharesIncluded in Dr. Belldegrun's cover-page total as of <date>March 31, 2026</date>
Bellco Legacy IV LLC holdings4,710,120 sharesOwned by Bellco Legacy IV LLC (managed by Dr. Belldegrun)
Bellco Legacy LLC holdings539,867 sharesOwned by Bellco Legacy LLC
"Row 9 of each Reporting Person's cover page to this sets forth the aggregate number"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared dispositive powerregulatory
"8 | Shared Dispositive Power 8,772,287.00"
Section 13(d)regulatory
"determining his obligations under Section 13(d) of the Exchange Act"
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 10)
Allogene Therapeutics, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
019770106
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
019770106
1
Names of Reporting Persons
Arie Belldegrun, M.D.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
4,694,096.00
6
Shared Voting Power
8,772,287.00
7
Sole Dispositive Power
4,694,096.00
8
Shared Dispositive Power
8,772,287.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
13,466,383.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.4 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
CUSIP Number(s):
019770106
1
Names of Reporting Persons
Bellco Legacy LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
539,867.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
539,867.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
539,867.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.2 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
019770106
1
Names of Reporting Persons
Bellco Legacy IV LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,710,120.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,710,120.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,710,120.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.9 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
019770106
1
Names of Reporting Persons
Vida Ventures LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
NEVADA
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,798,163.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,798,163.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,798,163.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.7 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
019770106
1
Names of Reporting Persons
Vida Ventures III, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
NEVADA
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,720,172.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,720,172.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,720,172.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.7 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
019770106
1
Names of Reporting Persons
Vida Ventures III-A, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
NEVADA
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,965.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,965.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,965.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.0 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Allogene Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
210 East Grand Avenue, South San Francisco, CA, 94080.
Item 2.
(a)
Name of person filing:
Arie Belldegrun
Bellco Legacy LLC
Bellco Legacy IV LLC
Vida Ventures LLC
Vida Ventures III, L.P.
Vida Ventures III-A, L.P.
(b)
Address or principal business office or, if none, residence:
Arie Belldegrun: 10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067
Bellco Legacy LLC: 10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067
Bellco Legacy IV LLC: 10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067
Vida Ventures LLC: 40 Broad Street, #201, Boston, MA 02109
Vida Ventures III, L.P.: 40 Broad Street, #201, Boston, MA 02109
Vida Ventures III-A, L.P.: 40 Broad Street, #201, Boston, MA 02109
(c)
Citizenship:
Arie Belldegrun: United States and Israel
Bellco Legacy LLC: Delaware
Bellco Legacy IV LLC: Delaware
Vida Ventures LLC: Nevada
Vida Ventures III, L.P.: Nevada
Vida Ventures III-A, L.P.: Nevada
(d)
Title of class of securities:
Common Stock
(e)
CUSIP No.:
019770106
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.
Row 9 of Dr. Belldegrun's cover page includes 3,866,329 shares of common stock issuable within 60 days of March 31, 2026 upon the exercise of stock options held by the Reporting Person and also includes (a) 4,710,120 shares of common stock beneficially owned by Bellco Legacy IV LLC, a limited liability company managed by Dr. Belldegrun and Rebecka Belldegrun, (b) 539,867 shares of common stock beneficially owned by Bellco Legacy LLC, a limited liability company owned and managed by trusts controlled by Dr. Belldegrun and Rebecka Belldegrun, (c) 1,798,163 shares of common stock beneficially owned by Vida Ventures LLC (Vida), a limited liability company of which VV Manager LLC is the manager, of which Dr. Belldegrun is a Senior Managing Director, (d) 1,720,172 shares of common stock beneficially owned by Vida Ventures III, L.P. (Vida III), a limited partnership of which Vida Ventures GP III, LLC (Vida GP III) is the manager, of which Dr. Belldegrun is a Senior Managing Director, and (e) 3,965 shares of common stock beneficially owned by Vida Ventures III-A, L.P. (Vida III-A), a limited partnership of which Vida GP III is the manager, of which Dr. Belldegrun is a Senior Managing Director. Dr. Belldegrun disclaims beneficial ownership of the shares held by Vida, Vida III and Vida III-A, except to the extent of any pecuniary interest therein, and other than for the purpose of determining his obligations under Section 13(d) of the Exchange Act.
(b)
Percent of class:
Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. This percentage is calculated based on 243,777,920 shares of common stock outstanding as of March 10, 2026, as reported in the Issuer's Quarterly Report on Form 10-K filed on March 12, 2026.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.
(ii) Shared power to vote or to direct the vote:
Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.
(iii) Sole power to dispose or to direct the disposition of:
Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.
(iv) Shared power to dispose or to direct the disposition of:
Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
Not Applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Arie Belldegrun, M.D.
Signature:
/s/ Arie Belldegrun
Name/Title:
Arie Belldegrun, M.D.
Date:
05/13/2026
Bellco Legacy LLC
Signature:
/s/ Arie Belldegrun
Name/Title:
By Arie Belldegrun, M.D., Manager
Date:
05/13/2026
Bellco Legacy IV LLC
Signature:
/s/ Arie Belldegrun
Name/Title:
By Arie Belldegrun, M.D., Manager
Date:
05/13/2026
Vida Ventures LLC
Signature:
/s/ Arie Belldegrun
Name/Title:
By VV Manager LLC, its Manager, By Arie Belldegrun, M.D., Senior Managing Director
Date:
05/13/2026
Vida Ventures III, L.P.
Signature:
/s/ Arie Belldegrun
Name/Title:
By Vida Ventures GP III, LLC, its Manager, By Arie Belldegrun, M.D., Senior Managing Director
Date:
05/13/2026
Vida Ventures III-A, L.P.
Signature:
/s/ Arie Belldegrun
Name/Title:
By Vida Ventures GP III, LLC, its Manager, By Arie Belldegrun, M.D., Senior Managing Director,
How many Allogene (ALLO) shares does Arie Belldegrun report owning?
The filing reports 13,466,383 shares beneficially owned by Arie Belldegrun and affiliated entities, representing 5.4% of the outstanding common stock based on the stated denominator.
What is the share count used to calculate the percentage in the Schedule 13G/A?
The percentage is calculated using 243,777,920 shares outstanding as of March 10, 2026, as referenced from the issuer's quarterly report filed March 12, 2026.
Does the filing include options or other exercisable securities?
Yes. The cover page for Dr. Belldegrun includes 3,866,329 shares issuable upon exercise of stock options within 60 days of March 31, 2026, which are included in the reported total.
Are all shares attributed to Dr. Belldegrun directly owned by him?
No. The filing lists shares held by affiliated entities (e.g., Bellco Legacy IV LLC, Vida Ventures entities) and states that Dr. Belldegrun disclaims beneficial ownership of certain Vida-held shares except for any pecuniary interest.
